Urothelial Carcinoma Clinical Trials
43 studies are recruiting for urothelial carcinoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.
Search these by distance from you
By city
Studies, page 2
-
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
This is a first-in-human (FIH), Phase 1 open-label, multicentre dose escalation study investigating AVA6000 monotherapy administered intravenously in patients with locally advanced (unresectable) or metastatic solid tumours that are likely to be FAP positive. The study consists of an initial Phase …
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Memorial Sloan Kettering Cancer Center, New York, New York
- Locations
- 9 in total
- Run by
- Avacta Life Sciences Ltd
-
Bladder Cancer Screening Trial
There is currently no accepted screening strategy for patients at high risk of developing bladder cancer. This study will ask patients to complete a urine test every 6 months for 2 years to help assess if routine screening helps finding bladder cancer at an earlier stage.
- Stage
- Not phased
- Ages
- 50 and older
- Site
- University of Texas Southwestern Medical Center, Dallas, Texas
- Run by
- University of Texas Southwestern Medical Center
-
Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence
This is a phase 2 study, single-arm study of adjuvant combination therapy with Sacituzumab Govitecan and Nivolumab in patients with muscle-invasive urothelial carcinoma of the bladder, ureter, or upper tract, who are high risk for cancer recurrence post curative-intent surgery based on surgical pat…
- Stage
- Phase 2
- Ages
- 18 and older
- Site
- Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California
- Run by
- University of California, Irvine
-
Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC
The goal of this clinical trial is to learn whether a combination of two chemotherapy drugs, Gemcitabine and Docetaxel, can treat high-grade non-muscle-invasive bladder cancer (HG-NMIBC) in adults whose cancer failed conventional BCG therapy. The drugs are given directly into the bladder (intravesi…
- Stage
- Phase 2
- Ages
- 18 to 99
- Site
- University of Iowa, Iowa City, Iowa
- Run by
- Michael A. O'Donnell
-
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Toripalimab in patients with advanced solid tumors who have exhausted all standard therapy available or are intolerant of the same.
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Dana Farber Cancer Institute, Boston, Massachusetts
- Locations
- 3 in total
- Run by
- Zumutor Biologics Inc.
-
Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments
The goal of this study is to better understand how to best treat participants with advanced bladder cancer who may not be able to tolerate all of the chemotherapy drugs that have been shown to be effective. In this study, investigators are assessing the role of the survey, the Geriatric-8, and its …
- Stage
- Not phased
- Ages
- 65 and older
- Site
- Dana-Farber Cancer Institute, Boston, Massachusetts
- Run by
- Dana-Farber Cancer Institute
-
Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy
Subjects will be randomized into 2 groups (stent or no stent) prior to radical cystectomy with ileal conduit urinary diversion (RCIC). They will follow the standard of care and be enrolled in the study for 12 months post-op. Risk of post-op complications will be analyzed.
- Stage
- Not phased
- Ages
- 18 to 85
- Site
- Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
- Locations
- 2 in total
- Run by
- Thomas Jefferson University
-
Circulating Tumor DNA Response In Urothelial Cancer
The purpose of this clinical trial is to evaluate the effectiveness of pembrolizumab monotherapy following 24 weeks of frontline pembrolizumab \& Enfortumab Vedotin (PEV) in patients with metastatic urothelial cancer (mUC).
- Stage
- Phase 2
- Ages
- 18 and older
- Site
- OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma
- Run by
- University of Oklahoma
-
An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
The purpose of this study is to understand the metabolism of cancers involving the kidney, including renal cell carcinomas and urothelial cell carcinomas, and how kidney cancers use different types of fuel to support tumor growth. This study uses specially labeled nutrient tracers of compounds norm…
- Stage
- Not phased
- Ages
- 18 and older
- Site
- University of Texas Southwestern Medical Center, Dallas, Texas
- Run by
- University of Texas Southwestern Medical Center
-
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Dren Investigational Site, Denver, Colorado
- Locations
- 10 in total
- Run by
- Dren Bio
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors. This study will be conducted in 3 parts. Part 1 is aimed at evaluating safety, tolerab…
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- University of Southern California, Los Angeles, California
- Locations
- 6 in total
- Run by
- Tanabe Pharma America, Inc.
-
Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC
This is a Phase 1a/1b, first-in-human (FIH), multi-center, open-label, non-randomized, dose escalation study, designed to determine the Maximum tolerated dose(MTD)/Recommended Phase 2 dose (RP2D) and to evaluate safety, tolerability, preliminary efficacy, pharmacokinetics, immunogenicity, pharmacod…
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- NEXT Oncology, Fairfax, Virginia
- Run by
- LG Chem
-
Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE)
This trial aims at investigating the diagnostic ability of a combined diagnostic panel including systematic endoscopic evaluation (SEE), blood-based ctDNA assay, and urine-based cfDNA assay to predict the presence of residual tumor remaining in the bladder at cystectomy. Patients who are planned fo…
- Stage
- Not phased
- Ages
- 18 and older
- Site
- University of Nebraska Medical Center, Omaha, Nebraska
- Locations
- 2 in total
- Run by
- Fox Chase Cancer Center
-
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…
- Stage
- Not phased
- Ages
- Any age
- Site
- Massive Bio SYNERGY-AI site, Birmingham, Alabama
- Locations
- 68 in total
- Run by
- Massive Bio, Inc.
-
Prospective Validation Study of High Volume Urine DNA Testing in Individuals With Suspicion of Urothelial Cancer
Urothelial cancers of the bladder and upper urinary tract account for over 200,000 deaths and 600,000 diagnoses annually worldwide. The most common presenting symptom is hematuria (blood in urine), triggering a cascade of tests, including an invasive examination of the bladder using a flexible scop…
- Stage
- Not phased
- Ages
- 18 to 100
- Site
- Vancouver Prostate Centre, Vancouver, British Columbia
- Locations
- 8 in total
- Run by
- Tampere University Hospital
-
Nephroureterectomy With and Without Lymph Node Dissection for Upper Tract Urothelial Cell Carcinoma
The goal of this study is to conduct the first randomized-controlled trial to determine the oncologic efficacy of lymph node dissection in participants with upper tract urothelial cell carcinoma. The main questions it aims to answer are: * To determine oncologic outcomes, specifically 2-year recurr…
- Stage
- Not phased
- Ages
- 19 and older
- Site
- University of Florida Health Science Center, Gainesville, Florida
- Locations
- 4 in total
- Run by
- Case Comprehensive Cancer Center
-
A Multicenter Cancer Biospecimen Collection Study
This study will collect de-identified tumor samples, with correlated clinical/demographic data and tissue histology, from patients selected or scheduled for pre-treatment tumor biopsy or who have had a recent pre-treatment tumor biopsy. These specimens and clinical data may be used in subsequent st…
- Stage
- Not phased
- Ages
- 18 and older
- Site
- Curebase, San Francisco, California
- Run by
- Cofactor Genomics, Inc.
-
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
The purpose of this registry is to evaluate real world experience and outcomes of patients with Upper Tract Urothelial Cancer (UTUC) treated with Jelmyto in the United States.
- Stage
- Not phased
- Ages
- 18 and older
- Site
- Providence St. Johns Health Center, Santa Monica, California
- Locations
- 22 in total
- Run by
- UroGen Pharma Ltd.
How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.
What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.
Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.